awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37693266-8DFFD1CA-B260-44EA-B89B-B5CACAB92C62
Q37693266-8DFFD1CA-B260-44EA-B89B-B5CACAB92C62
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37693266-8DFFD1CA-B260-44EA-B89B-B5CACAB92C62
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
P2860
Q37693266-8DFFD1CA-B260-44EA-B89B-B5CACAB92C62
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37693266-8DFFD1CA-B260-44EA-B89B-B5CACAB92C62
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
bd026e7bcda82c5f6c154d623c238e70bcd4bf47
P2860
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.